India emerging as a key player in the global pharmaceutical supply chain
News: India’s Contract Research, Development, and Manufacturing Organization (CRDMO) industry is set to double from USD 7 billion to USD 14 billion by 2028, growing at a 14% CAGR, according to a Macquarie Equity Research report.
Regulatory support, rising pharmaceutical outsourcing, and global supply chain shifts are driving this growth. The US Biosecure Act could further accelerate expansion, potentially pushing the market to USD 22 billion by 2030.
India’s cost advantage (30-40% lower than Western counterparts), strong regulatory approvals (USFDA, EMA), and expertise in APIs and speciality chemicals make it a preferred destination for pharmaceutical outsourcing. As global firms reduce reliance on China, India is emerging as a key player in the pharmaceutical supply chain.
Source: The Economic Times
Join The Community
Recent News
-
Trump Abandons Strait of Hormuz Transit Fee Plan, Prioritizes Gulf Trade Ties -
Russia Clears Rosatom–India Deal to Strengthen Northern Sea Route Partnership -
Logistics Sector Poised for Robust Q1 Revenue Growth Amid Margin Challenges -
NSA Ajit Doval Highlights Urgent Need for Collaboration Amid Supply Chain Disruptions -
West Asia Conflicts Drive MSME Exporters to Focus on Resilient Supply Chains
1 Comment